近日,据九源基因(2566.HK)官方消息,11月15日,公司骨修复产品骨优导®(含BMP-2骨修复材料)获得印尼卫生部的正式上市批准。这是该产品首次进入东盟国家市场,代表着公司在全球化布局上迈出关键一步。骨优导®是中国首款获批并商业化的含重组人BMP-2骨修复材料,研发需同时具备重组蛋白的生物制药能力及载体材料的医疗器械设计能力,技术壁垒高。在骨科领域,公司产品管线进展持续加速。新一代骨修复材料...
Source Link近日,据九源基因(2566.HK)官方消息,11月15日,公司骨修复产品骨优导®(含BMP-2骨修复材料)获得印尼卫生部的正式上市批准。这是该产品首次进入东盟国家市场,代表着公司在全球化布局上迈出关键一步。骨优导®是中国首款获批并商业化的含重组人BMP-2骨修复材料,研发需同时具备重组蛋白的生物制药能力及载体材料的医疗器械设计能力,技术壁垒高。在骨科领域,公司产品管线进展持续加速。新一代骨修复材料...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.